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Aaron Lerner's work provides a stunning set of examples of substances that help to transmit
information in the brain and body. His characterization of alpha-MSH and melatonin and his
sparking of interest in the further discovery of previously unknown substances have been of
inestimable value for the field of neurobiology. Efforts such as those that Lerner undertook so
successfully in the field ofinvestigative dermatology now constitute a major research thrust in the
field of behavioral neurochemistry and are directly related to advances in psychiatry and
neurology.
This review considers aspects ofresearch on the neuropeptides, with particular attention to the
endogenous opioid (morphine-like) peptides that are active on neural tissue. Neuropeptide
research can be categorized broadly as efforts to discover and characterize new families and
classes of active agents, investigations of their genetic and molecular processing, and studies of
their relationships to behavior in animals and human beings. This review selectively considers
some key research questions and strategies that arise from such research.
INTRODUCTION
Neuroregulators are substances that help to control chemical transmission between
and among nerve cells. They include both neurotransmitters, which are released from
one nerve cell to act on an adjacent one, and neuromodulators, which affect
transmission in a variety of other ways. Many classes of compounds fall into these
categories, including not only such classical agents as acetylcholine and the biogenic
amines but also the neuropeptides. Lerner's discovery of alpha-MSH [1] and
melatonin [2], members ofquite different chemical families, were two important steps
in the characterization ofpreviously unrecognized neuroregulators. Both are fascinat-
ing substances that have proven to be of great interest to those dedicated to
understanding how the brain works, and yet they areonly twoofwell over one hundred
neuroregulators that researchers have already identified [3].
For the past decade, neuropeptides have been especially crucial to the rapid
advances that have been occurring in basic and clinical neuroscience [4-6]. From
studies of neuropeptides have come new concepts and approaches for studying both
animal and human behavior and mental and neurological disorders [7]. For this
review, we have used the opioid peptides to illustrate some ofthe issues involved in the
study of the neuropeptides. We will consider current concepts of neuroregulation,
methods that have been used to find previously unrecognized neuropeptides, interrela-
tionships among the opioid neuropeptide systems, and clinical aspects of those
systems.
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THE CONCEPT OF NEUROREGULATION
Now a cornerstone ofneurobiology, the hypothesis that nerve cells communicate via
chemicals was first proposed only at the turn of this century [8]. Most of the first tests
of this hypothesis were done on peripheral nerve systems that use acetylcholine as the
neurotransmitter, and models of chemical neurotransmission are still strongly
influenced by the results of work on such peripheral systems. Neurotransmitters may
be defined as those compounds that relay an electrically promulgated signal from one
nerve cell to another that is closely adjacent to it via a structure-the synapse-
designed for that purpose; they are made and released presynaptically and act through
specific post-synaptic receptors to exert their effects. Typically, neurotransmitters are
viewed as rapidly turning nerve cells on and off. Gamma-aminobutyric acid (GABA)
and acetylcholine are prime examples of such substances.
More recent studies of neuroregulation, especially that mediated by neuropeptides
and other neuroactive substances in the brain, have added greatly to the number of
knownways in which substances can affect neuronal intercommunication. Discovery of
such additional mechanisms has demanded the introduction ofthe term neuromodula-
tion to round out the description of neuroregulatory processes [9-14]. Although
remarkably little still is known about theirspecific functions, neuromodulators may act
on many cells or may fine-tune neurotransmitter action. They must act to permit
specific alteration of nerve cell activity, rather than through a general increase or
decrease of neuronal metabolism. Neuromodulators can probably be subdivided into
two broad classes: synaptic neuromodulators, which act in synapses by altering the
dynamics of a neurotransmitter, and hormonal neuromodulators, which can act at a
distance, and in several sites, possibly through specific receptors.
In recent years a further elaboration of the concepts of neuromodulation has arisen
fromrecognition thatmultiple substances may be co-localized from a nerve cell and act
by various mechanisms on adjacent or regional nerve cells [15,16]. Many questions
remain unanswered about how these substances interact [17-19]. For example, it now
is clear that a single peptide precursor can contain a number ofneuroactive substances
and that that precursor may be processed differentially in various areas of the brain
[20-24]. The resulting possibilities for complex interactions among neuroregulators
within cells and brain regions are astonishing and still incompletely understood.
THE SEARCH FOR PREVIOUSLY UNRECOGNIZED NEUROPEPTIDES
Until only a few years ago, the neuroactive substances widely acknowledged to be
neuroregulators in the brain consisted ofacetylcholine and the biogenic amines. As we
noted earlier, many additional classes ofsubstances now appear to be neuroregulators,
and theneuropeptides, inparticular, have added to the number and complexity ofthese
identified systems. Various investigators have identified several dozen neuroactive
peptides over the past few decades, and additional dozens almost certainly still await
discovery.
Thevigorous search for such substances is vital for continued progress in behavioral
neurochemistry. Until the active substances are known, it is likely to be impossible to
relate neuroregulators to the range of behaviors, both normal and disturbed, with
which neuroscientists must be concerned. Often, key neuroregulator systems have
crucial homeostatic relationships with other systems, and optimal studies of their
physiology and pharmacologyrequire a detailed knowledge ofsuch relationships. The
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development ofthis area is hampered not only by the complexity ofthe natural systems
but also by the nomenclature and the lack of a "table of elements" with which to
predict relationships. As new substances are found, they generate a whole series of
investigations to determine their localization and functional relationships with other
neuroregulators, and that information in turn helps to define key features ofthe entire
system.
Neuroscientists have utilized six basic strategies to find endogenous neuropeptides.
They have searched for the substance responsible for a specific biological activity or
used a screening approach to identify a compound with a particular pharmacological
activity. More recently, some have used antibodies to recognize substances that are
structural analogs ofanother compound of interest and chemical assays with which to
recognize an important characteristic of peptides. Still others are using molecular
biological approaches, including the identification of precursor molecules, to detect
previously unknown neuroactive substances and likely cleavage products. Each ofthese
methods is providing valuable knowledge about important substances.
Lerner's own work beautifully illustrates the power of searching for an endogenous
substance with a highly specific biological action. His interest in compounds that could
stimulate melanocytes led to the discovery ofalpha-MSH [1]. The finding contributed
immediately to an understanding of skin physiology and later yielded insights into
brain function. Initially thought to be associated only with the pituitary, alpha-MSH
has been found more recently in other tissues, including the brain. Structural variants
of MSH are known to exist, and such variants may alter its activity in different tissues
or animal species. For example, in the rat, an acetylated form ofMSH is present in the
intermediate lobe of the pituitary but not in the brain [25]. Lerner's work also led to
the discovery of the important nonpeptide neuroregulator melatonin, which has some
biological actions that oppose those of alpha-MSH [2,26] and is important in
biological rhythms and some forms of depression. Investigators continue to demon-
strate the power of using specific biological activities to isolate neuropeptides, as
recently demonstrated in the identification ofcorticotropin releasing factor [27].
Less specific biological activities also can be pivotal in attempts to isolate neuroac-
tive peptides. For instance, a number of quite different neuroregulators may have
readily identifiable effects on a particular test system of broad general interest [28].
Thus, searches continue for substances that change blood pressure or alter smooth
muscle contractility.
The increasing facility with which researchers can identify specific receptors
involved in neural activity makes feasible a useful variant of this approach. Using a
receptor that typically is characterized by its interactions with one or more pharmaco-
logical agents, they search for endogenous ligands that act as specific agonists or
antagonists to that receptor activity [29].
Another effective approach uses immunological similarity among related sub-
stances. For example, an antibody raised against a key portion of a neuropeptide may
have substantial cross-reactivity with similar peptides. This approach has been used
successfully to find new opioid-like peptides, using an antibody that recognizes the
"universal" portion of known opioid peptides. Once detected by these methods, newly
discovered peptides are characterized by other methods [30-33].
An especially powerful technique for identifying new neuropeptides employs
chemical assays for specific derivatives. This approach has been pioneered in relation
to the search for endogenous amidated peptides-many of which have considerable
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biological activity. The development of a universal means of detecting and isolating
such peptides was the key step in identifying a series of new substances that appear to
have great importance [34]. This method does not permit researchers to predict a
priori what physiological or pharmacological activity a peptide will have, so some
neuroscientists havequestioned whether the search for such peptides is justifiable. We
reject that view. Each substance identified to date [35] has proven to be of great
interest, and thetechnique islikely to remain invaluable for uncovering the existence of
a number of peptides of biological interest that might otherwise have remained
unknown for many years.
Molecular neurobiology has led to new methods ofdetecting possible new neuroreg-
ulators by "reading" the gene sequences for neuroactive substances [36-38]. Often,
active substances, including much of their structure, have been predicted even before
the native peptides were isolated [39]. Related to these techniques have been
predictions of the structure of neuroactive peptides based on the structure of isolated
proteins orlarger peptides. The methods ofgene cloning enable researchers to discover
related neuropeptides much more rapidly once one member of a family has been
isolated. Yet, even with thesepowerful techniques, peptide sequencing must be used to
determine the actual structure of the peptide because of possible post-translational
modifications ofpeptides. Functional groups may be modified in key ways to produce
marked differences in biological activity [40-45].
THE OPIOID NEUROPEPTIDES AS A MODEL
The discovery of the opioid neuroregulators highlights many aspects of the search
for endogenous neuropeptides [46-49]. Three gene families (Table 1) are known to
yield opioid peptides in brain, an organ which contains over a dozen bioactive opioid
peptides [50]. Opioid neuropeptides also are present in many other tissues, including
the pituitary and adrenal [51]. Discovery of these fascinating substances has entailed
the use of several of the methods described above. For instance, discovery of
enkephalins was a result of the successful use of a pharmacological assay [46],
discovery ofbeta-endorphin entailedprediction from the structure ofa larger precursor
[52], and metorphamide was predicted largely from data about gene and protein
structure [53].
Interestingly, the various opioid neuropeptides have quite distinct neuronal effects,
withmanyacting onreceptors thatappear to bespecific for them. Even among a group
of closely related neuropeptides, neuroregulatory effects may differ markedly. The
dynorphin family of neuropeptides illustrates this point nicely: one form acts much
more rapidly and in different ways than another [54-56]. As noted earlier, specific
brain regions process the opioid peptide precursors in characteristic ways that may
differ markedly from other brain regions; as a result, even for a single gene family, the
ratio of active substances may vary greatly from region to region [21,57]. Learning
howneuropeptides areprocessed and what controls those mechanisms, especially when
neuroregulators are localized in the same neuron [58-64], are important directions for
future research. Elucidating the regulation of these steps will depend in part on
successful cloning of the genes for the enzymes involved in the processing.
Molecular biology may also provide essential tools for gaining a clearer understand-
ing of the role of receptors in mediating neuroregulators such as the neuropeptides
[54,65-68]. Studies ofreceptordevelopment and analysis ofreceptor localization with




From Proenkephalin From Prodynorphin From Proopiomelanocortin
Met-enkephalin (5) Leu-enkephalin (5) a-Endorphin (16)
Leu-enkephalin (5) Dynorphin A (1-8) (8) -y-Endorphin (17)
Met-enkephalin-Arg-Phe (7) fl-Neoendorphin (9) ,B-Endorphin (1-26) (26)
Met-enkephalin-Arg-Gly-Leu (8) a-Neoendorphin (10) f3-Endorphin (1-27) (27)
Metorphamide (8) Dynorphin B (13) f3-Endorphin (1-31) (31)
Bam 12 (12) Dynorphin A (17)
Bam 18 (18) Dynorphin B 29 (29)




Note: The number ofamino acids in each peptide is indicated in parentheses.
receptor labeling can enable researchers to obtain meaningful answers to a number of
fascinating questions about receptors for particular neuroregulators. How many
receptors are there? Is receptor function a result solely of protein sequence and
structure, or can local environmental effects alter activity? In what ways are the
receptors modified physiologically? Under what conditions does the number of
receptor molecules change, and how important are such changes? What regulatory
mechanisms control the formation and inactivation ofreceptors?
The opioid neuropeptides have been linked to a range ofphysiological processes and
behaviors [70-77]. A brief list includes such diverse behaviors as eating, pain
perception, stress-induced analgesia, learned helplessness, social behaviors, and some
forms of learning; however, efforts to study their roles in such processes pose serious
methodological difficulties [78]. The problems are illustrated in the next section,
which outlines some of the difficulties of linking the opioid neuropeptides to mental
disorders.
Successful behavioral investigations of the neuropeptides and other newly discov-
ered neuroregulators must be based on a firm understanding ofgenetic and biochemi-
cal regulatory mechanisms involved [79]. The complex interactions among the opioid
neuropeptides underscore the strong need to elucidate carefully the patterns of
involvement among the components ofthe opioid systems and with other neuroregula-
tor systems. Molecular neurobiology will markedly enhance the range of studies that
can be conducted, once it becomes feasible to investigate the kinetics ofthe expression
of the various steps involved in the formation and degradation of key elements of the
system, including the neuroregulator, its receptors, and essential synthetic and
degradative enzymes. Study of these complex interactions and of how behavior
changes them may be especially important for the future development of behavioral
neurochemistry.
ISSUES AND APPROACHES INVOLVED IN RELATING ENDOGENOUS
OPIOIDS TO MENTAL ILLNESS
The opioid neuropeptides provide an excellent example of the opportunities and
pitfalls oftrying to link a neuroregulator to some form ofmental illness [80]. Criteria
for linking a neuroregulator to a mental disorder include the following: (1) the
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neuroregulator must be formed endogenously and interact with receptor mechanisms
or other aspects of neuronal communication; (2) a characteristic pattern ofneuroregu-
lator activity or action should exist in relation to the mental disorder; (3) alteration of
the neuroregulator activity or ofa balance between the activities ofrelated neuroregu-
lator systems should alter the mental disorder; (4) appropriate manipulation of the
neuroregulator system, or those towhich it is linked, should induce thedisorder; and (5)
appropriate restoration of neuroregulator activity or balance should ameliorate the
mental disorder, unless the physiological process is irreversible. To date, no neuroregu-
lator system has been shown to meet even most of these criteria for a specific mental
disorder, but such concepts provide a framework for hypothesis-oriented research
[81,82].
A possible link between endogenous opioid neuropeptides and mental disorders is
appealing for several reasons. First, opiate drugs can have potent psychoactive effects,
including mood alteration and even hallucinations, and they sometimes have been used
in clinical treatment of major mental disorders [83]. Second, the presence of
endogenous opioids in brain regions associated with mood and behavior suggests
hypotheses regarding the possible involvement of endogenous opioids in mental
disorders, especially since they appear to be co-localized with other neuroregulator
systems also thought to be involved.
Hypotheses connecting neuroregulators with mental and addictive disorders typi-
cally posit that the latter result from a change in the former. Possible trouble sites
include neuroregulatory synthesis, storage, release, and inactivation, as well as
receptor mechanisms. For instance, a relative excess in the activity of an opioid
neuropeptide system, or a change in the balance between it and some related system,
could be offered as the etiological agent for some major mental disorder such as
schizophrenia, depression, or infantile autism. Tests of such hypotheses for the opioid
neuropeptides have employed two broad strategies [84]. One involves correlations
between the presence or absence of a given mental illness and concentrations of an
endogenous opioid neuropeptide ofinterest in samples oftissue, blood, hemodialysate,
or cerebrospinal fluid. Another entails the administration of an opioid agonist or
antagonist to patients with such major mental disorders asdepression orschizophrenia,
to assess the clinical effects of altering the neuropeptide system. Results from each of
these strategies highlight both why they are so attractive to investigators and some of
the serious pitfalls that they must try to avoid.
Any study of human psychopathology demands careful attention to the clinical
status of the patients who volunteer for the research [85]. That seemingly straightfor-
ward statement has been a major source of error for a great many neurobiological
studies of'severe mental illness. The resources of a specialized mental health clinical
research center typically are essential, for they enable investigators to recruit patient
volunteers to a safe environment where they can discontinue medications if necessary
and where standardized, reliable methods are available for diagnosing the disorders
and identifying and rating the severity of relevant symptoms. Only a handful of such
centers exist in this country, and the lack of qualified facilities and investigators has
been one ofthe problems with which the field has dealt.
Many of the most prevalent mental disorders are probably syndromes that may be
the end result of a number of dissimilar processes. Only some forms may be
predominantly biological, with others having major psychological or social contribut-
ing factors, and even within the mainly biological subtypes, only a fraction may result
584PEPTIDE NEUROREGULATORS
from disturbance ofa single neuroregulatory system. Unfortunately, researchers often
must treat these heterogeneous subtypes as a unitary entity because no valid and
reliable methods yet exist for identifying the subgroups. In the following descriptions
about opioid neuropeptides and schizophrenia and depression, no distinction is made
about subtypes for either of these disorders; yet, if only a small portion of the total
population has a disorder in the specific neuropeptide of interest, the abnormality in
that subgroup may be hidden in normal results for the vast majority ofsubjects.
Solutions to the conceptual problem of differentiating subtypes have not come
easily. Efforts to distinguish them clinically have not been completely satisfactory,
although they have been helpful at times. Similarly, biological tests or measures using
urine, blood, skin, and cerebrospinal fluid have not yet yielded the valid and reliable
markers needed-and psychiatric researchers naturally cannot obtain tissue samples
of brain in living patients. It seems likely that some of the newer methodologies for in
vivo studies of brain function and structure, including positron emission tomograph
(PET), computer-analyzed EEG, magnetic resonance spectroscopy and imaging, and
X-ray computed axial tomography, will provide new dimensions to clinical syndromes
that may be useful for subtyping.
The Measurement ofOpioid Peptides in Tissue, Blood, and CSF
Most studies of changes in the concentrations of opioid-like substances in patients
with mental disorders have used cerebrospinal fluid or plasma [86-90]. For example,
investigators have evaluated profiles of endorphin-like immunoreactivity in schizo-
phrenic patients, with contradictory results [86,91-100]. Several studies that used
cerebrospinal fluid reported interesting changes in the concentrations ofcertain peaks
and fractions; yet, agreement among the studies is relatively low with respect both to
the concentrations and to the characteristics ofthe opioid-like substances found.
Such contradictory results emphasize the need for more basic research to identify
endogenous opioid peptides in the cerebrospinal fluid, plasma, and tissue. Many
researchers have used radio receptor assays that have relatively poor specificity, so that
apparent differences between patients and controls may arise from factors completely
unrelated to the neuropeptide of interest. Radioimmunoassays that currently are
available for measuring opioids in a tissue, cerebrospinal fluid, and plasma also pose
problems. Often, radioimmunoassays are performed on crude or semicrude extracts,
with little effort to characterize the substance for which measurement is being sought.
When our group [101] attempted to measureopioid peptides in cerebrospinal fluid, we
detected measurable displacement in our radioimmunoassays but analysis of that
immunoreactivity showed that it did not behave identically with a standard curve for
the opioid peptides under study.
Ourfinding raisesquestions about whatinvestigators are measuring in cerebrospinal
fluid. Salt, lipid, or other compounds may interfere with the antibody and antigen
complex, a similar peptide with a different affinity for the antibody may interfere, or a
biologically inactive metabolite of the peptide under study may compete for the
antibody. Most publications that purport to measure neuropeptides in cerebrospinal
fluid using radioimmunoassays have not considered these problems. Until the validity
of an assay method for a specific peptide is confirmed, its use to study the role of that
peptide in a mental disorder is premature and likely to yield unreliable results.
For opioid neuropeptides, as with other neuropeptides, researchers who are inter-
ested in clinical applications will need to ensure that the peptides under study have
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been isolated from the fluid under study and characterized definitively and that
parameters of valid assay are established before the studies begin. It is unlikely that
measurements of the opioid neuropeptides as a class will be useful or feasible; rather,
studies are needed that quantitate specific substances or groups ofsubstances from the
three known gene families. Measures of the substances as a group could provide a
general assessment of whether opioid peptides are "increased" or "decreased," but a
negative finding might mask an important change in the ratio of two or more key
substances that did not result in an overall change in total concentration.
Despite their brief history, opioid neuropeptides already are associated with some
controversies in psychiatric research. For example, one finding stemmed from an
uncontrolled trial that suggested that hemodialysis might decrease symptoms in
patients with schizophrenia [102]. An analysis of the changes in the dialysates over
time led to a report that a leucine form of beta-endorphin decreased as the patients
improved, leading promptly to the hypothesis that leu-endorphin was causing symp-
toms of schizophrenia [103]. The issues were several: (1) does hemodialysis improve
schizophrenia; (2) does dialysis result in removal ofleu-endorphin; and (3) is the latter
compound involved in the symptoms of schizophrenia? The answer to each of the
questions to date has been a clear-cut "no." Other researchers were unable to confirm
the effectiveness of dialysis in schizophrenia [104,105]. Furthermore, no investigator
has been able to confirm the finding ofa leucine form ofbeta-endorphin in any species;
indeed, it is not found in any of the three gene families of opioid neuropeptides that
have been isolated and characterized [106]. Also, a double-blind study showed that the
total concentration of beta-endorphin-like substances is not elevated in plasma of
patients with schizophrenias and that the concentrations of such substances are not
consistent with the levels of the endorphin-like material reported earlier in the
dialysates [107]. Although clinically relevant changes in the pattern of opioid
neuropeptide concentrations in the plasma ofschizophrenic patients may ultimately be
identified, existing results strongly suggest that the original report was not valid.
Studies ofopioid peptides in plasma and tissue present some ofthe same problems as
those done with cerebrospinal fluid. Plasma, in particular, has provided relatively
nonspecific measurements. Investigators typically describe their results in terms of
"opioid-like" activity, which may be inadequate. The wide range ofvalues reported by
different investigators and the apparent nonspecificity of the assays underscore these
difficulties. Even so, such studies eventually may be of interest, for there is reason to
believe that plasma contains a number ofendogenous opioid substances. The pituitary
and adrenal glands may both release opioid peptides in times ofstress, and a thorough
understanding ofwhat substances are there, what they aredoing, and how their release
patterns change in relation to stress therefore may be ofconsiderable importance.
Studies ofneuropeptide concentrations and distributions in human autopsy material
may be particularly valuable, especially in these nascent phases ofresearch (see [7] for
a series of papers measuring various peptides in which autopsy material was utilized
from patients with neurological conditions). With such samples, it is possible not only
to investigate patterns of neuropeptide distribution but also to characterize their
receptor distribution and activity. Such studies may require material obtained quite
soon after death, and further work is needed to definewhat happens to these substances
at the time of and immediately after death [108]. Particularly promising would be the
use of the tools of molecular neurobiology to investigate the altered patterns of
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neuropeptide systems. Evidence increasingly suggests that such studies can be
conducted even in autopsy material.
Administration ofan Opioid Agonist-Studies with Beta-Endorphin
Studies of beta-endorphin probably have attracted the most attention of any of the
clinical trials of opioid agonists. The first reports [109,110] suggested that a single
intravenous injection of beta-endorphin could produce dramatic, lasting symptom
reliefin patients with depression and schizophrenia, but these were not performed with
adequate controls. Subsequent, more carefully controlled studies have not supported
the initial findings. For example, in a double-blind study in which patients were
administered 20 mg of beta-endorphin intravenously, no change was observed in
schizophrenic symptoms either by the research staff or by the patients [ 11,112]. The
researchers were able to show that this dosage of beta-endorphin did have central
effects, however, as evidenced by a marked increase in prolactin secretion [111] and by
an increase in alpha rhythm on EEG [113]; both ofthese central effects also occur with
morphine administration. The physiological effects of beta-endorphin, which lasted
about 30 minutes, might have reflected either peripheral changes that were then
transmitted to the brain or direct central actions ofthe drug on receptors at locations in
the brain where the blood-brain barrier is open to macromolecules. Other double-blind
studies of schizophrenic subjects confirm that behavior is not improved after a single
dose of beta-endorphin [114-116]. Research on a non-opioid endorphin des-tyrosine-
gamma-endorphin has also been disappointing, despite early enthusiasm [117-123].
Opioid agonists may be more useful for treating depression than schizophrenia
[124-133]. The administration of opioid agonists appears to cause some depressed
patients to switch into mania, and exogenous opioids are reported to affect mood in
ways that are consistent with such findings. Again, results of the studies are somewhat
contradictory, and the numbers of subjects have been quite limited in each study, so
that varying findings may reflect, in part, the characteristics of the patients or of their
subtype. Nevertheless, on the basis of the evidence currently at hand, one might
hypothesize that a relative deficiency of beta-endorphin or a change in the ratios of
endogenous opioid peptides could play an etiological role in some forms of depression.
Although the reports to date on beta-endorphin have been largely negative, the basic
strategy of using agonists appears to have merit for studying connections between
opioid neuropeptides and specific forms of mental illness. A number of investigators
are trying to develop various peptide and nonpeptide analogs that can be studied
directly in analogous research designs [124-126].
One of the problems with intravenous injections of beta-endorphin and other
neuropeptides is their relative impermeability to the blood-brain barrier, so that little
of the administered drug gets into the brain. One way of avoiding these difficulties
would be to administer beta-endorphin or other endogenous opioid peptides directly
into the cerebrospinal fluid. A precedent for such studies is the evidence that
intrathecal injections of beta-endorphin or morphine by lumbar puncture produce a
profound analgesia [134-139]. Some of these studies were performed on patients who
had required substantial doses of morphine by more traditional routes for even partial
pain relief. Others used intrathecal beta-endorphin to produce analgesia in obstetrical
patients. Taken together, the results suggest that the effects of beta-endorphin when
administered in this way may be long-lasting. The reports indicate that patients have
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appeared normal behaviorally, although a few have felt drowsy; however, little specific
attention has been given to the psychological responses ofthese patients. The evidence
is at least suggestive that higher doses may induce a manic psychosis.
In general, available studies seem to support the value of a new trial of beta-
endorphin in depression, using intrathecal administration of low doses, e.g., 1 mg, of
the drug. Other endogenous opioid neuropeptides or their derivatives could also be
studied, in efforts to uncover possible relationships between specific opioid systems and
forms ofdepression. Individuals who are resistant toother forms oftreatment might be
appropriate candidates for a single dosage in a double-blind, cross-over design that
could thereby permit evaluation ofthe results with fewer problems ofartifact.
The studies with beta-endorphin highlight many problems associated with investi-
gating effects ofa particular neuroregulator in relation to mental illness. The necessity
of double-blind studies, including the use of placebo trials, is clear, as is the need to
establish that the agent is having a definable central effect. In the early studies,
beta-endorphin cost an estimated $10,000 per injection. With the starkly limited
budgets for mental health research, key questions simply could not be addressed. For
example, to what extent do differences in drug dosage and route alter the outcome of
various treatments? Would results differ if the peptide or an analog could be
administered on a more prolonged basis? Perhaps the development of less expensive
but more effective derivatives would make it possible to address such questions more
directly.
The impact on public expectations of some of the early studies of endorphin and
mental disorders also raises broader questions about the communication of medical
information at its most preliminary stages. Research efforts perforce may deal with
patients who sometimes are untreatable with current methods. The families ofpersons
with chronic schizophrenia are particularly susceptible to new "cures," even if the
evidence is slim or nonexistent. The use of dialysis in schizophrenia illustrates the
potential impact of this situation concerning the necessity for care in obtaining data
and in presenting it.
Studies Utilizing OpioidAntagonists-The Use ofNaloxone
The strategy of using opioid antagonists in studies of mental disorders is both
interesting and potentially powerful. Naloxone and naltrexone are the only two
antagonists to receive widespread use in studies to date. Ofthese, naloxone, which has
a more complete opiate antagonist effect, has been tested more extensively, despite its
short duration ofaction and the need to administer it intravenously.
Limited trials of naloxone in depression and mania have been inconclusive, and the
data generally indicate no change. However, a series of reports suggest that naloxone
can induce quite specific changes in patients with schizophrenia. This topic now has an
extensive though as yet unresolved history [140-1551. The first report of an attempt to
reverse schizophrenic symptoms with naloxone came from the Swedish group who had
earlier reported that certain endorphin-like fractions were elevated in cerebrospinal
fluid. In a single-blind study, low doses ofnaloxone reduced auditory hallucinations in
some patients. Several groups tried to replicate the result with mixed success at that
dose. One interesting study found an altered pain threshold in some schizophrenics,
which opioid antagonists appeared to alter [156].
The Stanford study of naloxone and schizophrenia provided the first extensive,
double-blind study ofthe effects ofa relatively high dose ofnaloxone on hallucinations
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[157,158]. Thestudy, which still is ongoing, has involved screening of 1,800 individuals
to identify 18 subjects who met the Research Diagnostic Criteria for schizophrenia,
exhibited chronic and nearly constant hallucinations, and were able and willing to
participate in the study. Patients with chronic hallucinations were used because of
naloxone's presumed short period of action. The study has utilized a double-blind
cross-over design in which patients received either saline or istered 10 mg of naloxone
and then were followed for two days after the infusion.
In the Stanford study, naloxone reduced or eliminated hallucinations in half of the
patients for about two hours after administration. Typical was the responseofa patient
who commented, "The hallucinations are like a little radio attached to my ear that is
always on, only now I cannot hear the radio." The result was a surprise. Many of the
earlier studies had not examined time points beyond the traditionally short period of
action normally associated with naloxone in opiate overdose situations. Since the initial
report from Stanford, other groups have confirmed the positive findings using longer
time periods and higher doses. The most extensive replication has been a multicenter
study conducted by the World Health Organization (WHO), which reported a
significant reduction ofschizophrenic hallucinations [159].
Taken as a whole, the body of literature about reduction of hallucinations in
individuals with schizophrenia is relatively consistent, at least for those studies that
utilized a double-blind paradigm with a relatively high dose of naloxone. The positive
studies report improvement in auditory hallucinations, psychotic symptoms, unusual
thought content, or tension. Nevertheless, these signs and symptoms are not normally
thought of as involving the same underlying factors. It is also interesting that the
effects occur at a time period beyond that normally associated with the effects of
naloxone and at quite high doses, raising the question of whether the effect is indeed
due to a blockade of the opiate system or to a secondary effect on that system of an
effect on some other system. It is clear that further studies of opiate antagonists in
schizophrenia are merited. Ultimately such attempts must be based on the use of
antagonists that act on specific receptors which have been described for the endoge-
nous opioid systems.
CONCLUSIONS
A decade after the discovery of the opioid-peptide neuroregulators, few would
contest their importance for understanding brain function and behavior. A number of
areas appear ripe for further study, including resolution of issues regarding the
regulation and processing of neuropeptides in brain regions and delineation of the
controls of those mechanisms. Also important is elucidation of the genetic limits on
such regulation and the ways in which developmental, behavioral, and environmental
factors can influence processing. Although a variety ofopioid neuropeptides have been
found, others await discovery. Some of these newly discovered neuroregulators will fit
within the three genes already known to provide progenitors ofthe opioid peptides, but
others may offer clues tootherorigins. Themultiplicity ofthe opioid neuropeptides and
the diversity of their receptors may enable researchers to study the ways in which
related systems function and interact. The complexity of the systems highlights the
importance of anatomical and neurophysiological studies of them individually and
together, as well as in combination with the various other neuroregulators with which
they are co-released.
The opioid neuropeptides are already known to be important in a variety of
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behaviors. Nevertheless, underlying mechanisms, including the relationships to other
systems, remain to be established. In the future, researchers must study how behavior
alters neurochemical processes and in turn is altered by them. Consideration of these
reciprocal relationships, which may involve changes at any stage in neuroregulator
mechanisms from formation to release and receptor interactions, will be critical to the
continued advances of behavioral neurochemistry as a discipline. In the long term,
identification ofsuch interactions between behavior and neurochemistry will also prove
critical to understanding severe mental disorders. Causal processes between endoge-
nous opioid peptides and forms ofdepression, schizophrenia, and opiate addiction have
already been posited.
The ability to study relationships between peptides and other neuroregulators and
behavioral states, including disorders of behavior, rests heavily on the development of
basic information about the characterization and regulation of neuropeptide systems.
In that context, discovery of previously unrecognized neuroactive agents is a key step,
as is basic research on such substances once they have been identified.
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